RGNX

⬣ Class Action

REGENXBIO Inc.

Securities Class Action Lawsuit

Class Period: February 9, 2022 – January 27, 2026
Lead Plaintiff Deadline: April 14, 2026

What Is the REGENXBIO Inc. (RGNX) Class Action Lawsuit About?

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired REGENXBIO securities between February 9, 2022, and January 27, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.

What Does the REGENXBIO Inc. Securities Class Action Allege?

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

  1. (1) REGENXBIO’s representations concerning its plan to develop and commercialize RGX‑111, a one‑time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, were materially misleading;
  2. (2) Defendants’ positive statements regarding the anticipated success of RGX‑111’s Phase I/II clinical trial, purportedly supported by continuing favorable biomarker and safety data, lacked a reasonable basis;
  3. (3) the efficacy and safety profile of RGX‑111 was materially overstated; and
  4. (4) as a result, Defendants’ statements about REGENXBIO’s business, operations, and prospects were materially false and misleading at all relevant times.

What’s Next for REGENXBIO Investors?

A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in REGENXBIO you have until April 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

How Is REGENXBIO (NASDAQ: RGNX) Stock Trading Today?

Interactive chart showing the weekly share price history of RGNX (RGNX).

Filed Complaint

Review the full class action complaint as filed in court.

View PDF

How Is BG&G Representing Investors in Securities Class Actions?

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”
— Peretz Bronstein, Founding Partner

Other Active Cases

ASTS Class Action

AST SpaceMobile, Inc.

Lead Plaintiff Deadline

November 13, 2026

View Case →
BIDU Class Action

Baidu, Inc.

Lead Plaintiff Deadline

November 13, 2026

View Case →
APP Class Action

AppLovin Corporation

Lead Plaintiff Deadline

November 16, 2026

View Case →
All Cases

View All Upcoming Deadlines

View Cases →

Investor Guides

Practice AreaHow Securities Class Actions WorkHow cases are filed, what the lead plaintiff deadline means, and how investors recover losses.Learn More →
Investor Guide

What Is a Lead Plaintiff in a Class Action Lawsuit?

Investor Guide

What Is the Deadline to File a Securities Fraud Claim?

Investor Guide

How Do Securities Class Action Settlements Work?

The deadline for lead plaintiff for this case has passed.

Thank you for your interest.